首页> 外文期刊>Journal of cardiovascular risk >Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes.
【24h】

Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes.

机译:无糖尿病患者一级预防的心血管风险评估的准确性。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND The burden of atherosclerosis has led to treatment prioritization on high-risk individuals without established cardiovascular disease based on risk estimates. We investigated the effects of biological variation in risk factors on risk estimate accuracy and whether current primary prevention screening (risk assessment) models correctly categorize patients.METHODS A population of 10 000 'perfect' individuals with 100 simulants affected by biological and analytical variation for systolic blood pressure, total cholesterol, high-density lipoprotein-cholesterol was mathematically modelled. Coronary heart disease (CHD) risks were calculated using the Framingham study algorithm and the mathematical properties of the screening system were evaluated.RESULTS At internationally recommended 10-year CHD risk treatment threshold levels of 15, 20 and 30%, the 95% confidence intervals were +/- 5.1, +/- 6.0 and +/- 6.9% for single-point (singlicate), +/- 3.6, +/- 4.2 and +/- 4.9% for duplicate and +/- 2.8, +/- 3.3 and +/- 3.9% for triplicate estimates respectively (i.e. for singlicate 15% risk, 95% confidence interval is 9.9-20.1%). Consequently, using the 30% risk threshold from the National Service Framework (NSF) for CHD with singlicate estimation, 30% of patients who should receive treatment would be denied it and 20% would receive treatment unnecessarily. Multiple measurements improve precision but cannot absolutely define risk. Blood pressure should be measured to the greatest accuracy possible and not rounded prior to averaging.CONCLUSIONS This study suggests biological variation in cardiovascular risk factors has profound consequences on calculated risk for therapeutic decision-making. Current guidelines recommending multiple measurements are usually ignored. Triplicate measurement is required to allow risk to be identified and clinical judgement has to be exercised in interpretation of the results.
机译:背景技术动脉粥样硬化的负担已经导致在没有基于风险估计的确定的心血管疾病的高风险个体上优先进行治疗。我们调查了危险因素中的生物学变异对风险估计准确性的影响以及当前的一级预防筛查(风险评估)模型是否正确地对患者进行了分类。方法10,000例``完美''个体中有100例模拟行为受收缩压和生物学变异性影响可以对血压,总胆固醇,高密度脂蛋白胆固醇进行数学建模。使用Framingham研究算法计算冠心病(CHD)风险,并评估筛查系统的数学特性。结果在国际推荐的10年CHD风险治疗阈值水平分别为15%,20%和30%时,置信区间为95%单点(单点)分别为+/- 5.1,+ /-6.0和+/- 6.9%,重复点分别为+/- 3.6,+ /-4.2和+/- 4.9%,以及+/- 2.8,+/-一式三份的估计值分别为3.3%和+/- 3.9%(即,对于15%的风险,95%的置信区间为9.9-20.1%)。因此,使用来自国家服务框架(NSF)的30%冠心病危险阈值进行单次估算,应接受治疗的30%患者将被拒绝接受治疗,而20%的患者将不必要地接受治疗。多次测量可以提高精度,但不能绝对定义风险。血压应尽可能精确地测量,并且在取平均值之前不得四舍五入。结论本研究表明,心血管疾病危险因素的生物学差异会对治疗决策的计算风险产生深远影响。通常会忽略当前建议进行多次测量的准则。需要三重测量以识别风险,并且在解释结果时必须进行临床判断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号